Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2023-10-30 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
关于以集中竞价交易方式首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first share repurchase through centralized bidding. It details the number of shares repurchased, prices, compliance with regulatory rules, and plans for future repurchases. It does not contain financial statements or performance data but is a disclosure of a share buyback transaction. This fits the definition of a Transaction in Own Shares (POS) filing, which reports the company's buyback of its own shares.
2023-10-30 Chinese
回购报告书
Transaction in Own Shares Classification · 100% confidence The document is titled '回购报告书' which translates to 'Repurchase Report' or 'Buyback Report'. It details the company's plan to repurchase its own shares using its own funds, specifying the purpose (employee stock ownership plan or equity incentive plan), the price limits, the number of shares, the funding source, the implementation period, and the authorization by the board. It also includes risk disclosures, independent director opinions, and procedural details related to the share buyback. This is a detailed report about the company's share repurchase plan and execution, not just an announcement or a brief summary. The content matches the definition of a 'Transaction in Own Shares' filing, which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length (7351 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the correct classification is POS (Transaction in Own Shares).
2023-10-29 Chinese
关于参与河南信心药业有限公司破产重整进展的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Enwei Pharmaceutical Co., Ltd. regarding its participation in the bankruptcy reorganization progress of Henan Xinxin Pharmaceutical Co., Ltd. It details the voting results on the reorganization plan draft by various creditor groups, the company's investment amount, and the potential risks and impacts of the reorganization. The document is a formal public announcement about a corporate restructuring event, specifically a bankruptcy reorganization, and does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor is it a call transcript or audit report. It is also not a merger or acquisition filing but relates to a restructuring process. Given the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-10-27 Chinese
关于回购股份事项前十名股东及前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the company's share repurchase plan and details the top ten shareholders and top ten unrestricted shareholders as of the day before the repurchase decision. It references the board meeting approving the share repurchase and provides specific shareholding data. The content focuses on shareholding and repurchase details rather than financial results or management changes. It is not a full financial report, earnings release, or management report. It is not a voting result announcement or a regulatory filing about legal or governance matters. The document fits the category of a Transaction in Own Shares (POS) because it relates to the company's share buyback plan and shareholder holdings relevant to that transaction.
2023-10-26 Chinese
2023年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第三季度报告' which translates to '2023 Third Quarter Report'. It contains detailed financial data including revenue, net profit, cash flow, earnings per share, and changes in assets and liabilities for the third quarter period ending September 30, 2023. It also includes shareholder information and detailed financial statements such as the consolidated balance sheet. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive quarterly financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2023
2023-10-26 Chinese
关于向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Enwei Pharmaceutical Co., Ltd. regarding the company's application for a comprehensive credit line from several banks. It details the board meeting resolution approving the credit application, the amount, terms, and the authorization given to the chairman to handle related matters. The document is short (931 characters) and focuses on financing activities, specifically credit/loan arrangements. It is not a full financial report, audit, or earnings release. It is not a report publication announcement or certification. The content fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-10-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.